Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland
Open accessThe DOI matches its Crossref record; 35 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the contemporaneous prevalence of diabetic peripheral neuropathy (DPN) in people with type 1 diabetes (T1D) in Scotland and study its cross-sectional association with risk factors and other diabetic complications. RESEARCH DESIGN AND METHODS: We analyzed data from a large representative sample of adults with T1D (N = 5,558). We assessed the presence of symptomatic neuropathy using the dichotomized (≥4) Michigan Neuropathy Screening Instrument Patient Questionnaire score. Logistic regression models were used to investigate associations between DPN and risk factors, as well as with other complications. RESULTS: The burden of DPN is substantial with 13% prevalence overall. Adjusting for attained age, diabetes duration, and sex, the odds of DPN increased mainly with waist-to-hip ratio, lipids, poor glycemic control (odds ratio 1.51 [95% CI 1.21–1.89] for levels of 75 vs. 53 mmol/mol), ever versus never smoking (1.67 [1.37–2.03]), and worse renal function (1.96 [1.03–3.74] for estimated glomerular filtration rate levels <30 vs. ≥90 mL/min/1.73 m2). The odds significantly decreased with higher HDL cholesterol (0.77 [0.66–0.89] per mmol/L). Living in more deprived areas was associated with DPN (2.17 [1.78–2.65]) for more versus less deprived areas adjusted for other risk factors. Finally, individuals with prevalent DPN were much more likely than others to have other diabetes complications. CONCLUSIONS: Diabetic neuropathy remains substantial, particularly affecting those in the most socioeconomically deprived groups. Those with clinically manifest neuropathy also have a higher burden of other complications and elevated levels of modifiable risk factors. These data suggest that there is considerable scope to reduce neuropathy rates and narrow the socioeconomic differential by better risk factor control.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · cited 1×
“73m2) were computed using the CKD Epidemiology Collaboration formula eGFR (24).”
MethodMultimodel Inference: Understanding AIC and BIC in Model Selection
Burnham, K. P., & Anderson, D. R. (2004) · Sociological Methods & Research · doi:10.1177/0049124104268644 · Cited by 11,648
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Vascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Diabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211 · cited 1×
“Drug treatment of DPN mainly comprises symptom control using anticonvulsants and antidepressants (7,12, 13), with duloxetine and pregabalin being among the first-line therapies indicated in the major guidelines (14).”
BackgroundTesfaye, S., Stevens, L. K., Stephenson, J. M., Fuller, J. H., Plater, M., Ionescu-Tirgoviste, C., Nuber, A., Pozza, G., & Ward, J. D. (1996) · Diabetologia · doi:10.1007/s001250050586 · Cited by 695 · cited 4×
“The data reinforce previous findings (26) and give support to the idea of a holistic, comprehensive approach to diabetes management.”
BackgroundResultInfluentialLiew, G., Michaelides, M., & Bunce, C. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004015 · Cited by 663
Herman, W. H., Pop‐Busui, R., Braffett, B. H., Martin, C. L., Cleary, P. A., Albers, J. W., Feldman, E. L., & The DCCT/EDIC Research Group (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03644.x · Cited by 493
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487 · cited 2×
“, youth, community-based, or hospital based-settings) (1,4,14,34).”
BackgroundMaser, R. E., Steenkiste, A. R., Dorman, J. S., Nielsen, V. K., Bass, E. B., Manjoo, Q., Drash, A. L., Becker, D. J., Kuller, L. H., Greene, D. A., et al. (1989) · Diabetes · doi:10.2337/diab.38.11.1456 · Cited by 408
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study
Stephenson, J., Fuller, J. H., & EUROBIAB IDDM Complications Study Group (1994) · Diabetologia · doi:10.1007/bf00398055 · Cited by 345 · cited 1×
“15 combination of symptoms, clinical and neurophysiological assessments in a group of clinic-attending insulin-dependent patients aged 15 to 60 (36).”
BackgroundJaiswal, M., Divers, J., Dabelea, D., Isom, S., Bell, R. A., Martin, C. L., Pettitt, D. J., Saydah, S., Pihoker, C., Standiford, D. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0179 · Cited by 303 · cited 1×
“(35) reported a prevalence of 7% in youth with T1D from the SEARCH for Diabetes in Youth study using the clinical examination from the Michigan Neuropathy Screening Instrument,which is comparable to our estimated prevalence of”
MethodAndersen, S. T., Witte, D. R., Dalsgaard, E.-M., Andersen, H., Nawroth, P., Fleming, T., Jensen, T. M., Finnerup, N. B., Jensen, T. S., Lauritzen, T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2062 · Cited by 248 · cited 1×
“We defined symptomatic DPN based on the MNSIQ (17), using the validated threshold of a MNSIQ score of 4 or more (21) as evidence of the presence of symptomatic DPN; this criterion was also used in a recent study to define DPN (22).”
MethodEpidemiology of polyneuropathy in diabetes and prediabetes
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-53480-4.00001-1 · Cited by 235 · cited 1×
“, youth, community-based, or hospital based-settings) (1,4,14,34).”
Diabetic Foot Problems: Prevention and Management
Internal Clinical Guidelines Team (2015) · Cited by 218
Mishra, S. C., Chhatbar, K. C., Kashikar, A., & Mehndiratta, A. (2017) · BMJ · doi:10.1136/bmj.j5064 · Cited by 210
Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015
Papanas, N., & Ziegler, D. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.48 · Cited by 207
Selvarajah, D., Cash, T., Davies, J., Sankar, A., Rao, G., Grieg, M., Pallai, S., Gandhi, R., Wilkinson, I. D., & Tesfaye, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138224 · Cited by 178 · cited 1×
“The tests only detect neuropathy at an advanced stage (8,9).”
BackgroundFrequency of evidence-based screening for retinopathy in type 1 diabetes
The DCCT/EDIC Research Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612836 · Cited by 141
Hothersall, E. J., Livingstone, S. J., Looker, H. C., Ahmed, S. F., Cleland, S., Leese, G. P., Lindsay, R. S., McKnight, J., Pearson, D., Philip, S., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2118 · Cited by 128 · cited 1×
“These linked data included diabetesrelated information from the Scottish Care Information-Diabetes Collaboration (SCI-DC) database (19), the Scottish Renal Registry, and routine data from Information Services Division Scotland such as hospital admissions data (Scottish Morbidity Record SMR01).”
MethodSelf-citationTesfaye, S. H., & Kempler, P. (2005) · Diabetologia · doi:10.1007/s00125-005-1721-7 · Cited by 113 · cited 1×
“Hence, patients suffering from DPN experience a deterioration of their quality of life (1,3,4).”
BackgroundElliott, J., Jacques, R. M., Kruger, J., Campbell, M. J., Amiel, S. A., Mansell, P., Speight, J., Brennan, A., & Heller, S. R. (2014) · Diabetic Medicine · doi:10.1111/dme.12441 · Cited by 112
British National Formulary (BNF)
Thompson, D. (2005) · Cited by 111
N-Glycan Profile and Kidney Disease in Type 1 Diabetes
Bermingham, M. L., Colombo, M., McGurnaghan, S. J., Blackbourn, L. A. K., Vučković, F., Pučić Baković, M., Trbojević-Akmačić, I., Lauc, G., Agakov, F., Agakova, A. S., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1042 · Cited by 100
Self-citationReduced Incidence of Lower-Extremity Amputations in People With Diabetes in Scotland
Kennon, B., Leese, G. P., Cochrane, L., Colhoun, H., Wild, S., Stang, D., Sattar, N., Pearson, D., Lindsay, R. S., Morris, A. D., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0511 · Cited by 95 · cited 1×
“For example, diabetes is no longer the leading cause of blindness in England andWales (15); the incidence of lower-extremity amputations in Scotland was reduced (16).”
BackgroundSelf-citationRates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme
Looker, H. C., Nyangoma, S. O., Cromie, D. T., Olson, J. A., Leese, G. P., Black, M. W., Doig, J., Lee, N., Lindsay, R. S., McKnight, J. A., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303948 · Cited by 76 · cited 1×
“(25), with the grading of the worst eye being used.”
BackgroundSelf-citationUpdate on the Management of Diabetic Neuropathy
Ang, L., Cowdin, N., Mizokami-Stout, K., & Pop-Busui, R. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0036 · Cited by 55 · cited 1×
“The tests only detect neuropathy at an advanced stage (8,9).”
BackgroundCohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO)
Akbar, T., McGurnaghan, S. J., Palmer, C. N. A., Livingstone, S. J., Petrie, J. R., Chalmers, J., Lindsay, R. S., McKnight, J. A., Pearson, D. W. M., Patrick, A. W., et al. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw152 · Cited by 21 · cited 14×
“This definition was likely to underestimate the prevalence of symptomatic DPN, and we performed sensitivity analyses usingMNSIQ thresholds of 3 and 2, leading to the higher crude prevalence estimates of 19.4% and 35.2%, respectively.”
ResultInfluentialSelf-citationon behalf of the OPTION-DM group, Selvarajah, D., Petrie, J., White, D. A., Julious, S. A., Bortolami, O., Cooper, C. L., Bradburn, M. J., Loban, A., Bowler, H., et al. (2018) · Trials · doi:10.1186/s13063-018-2959-y · Cited by 16 · cited 1×
“7% of them were taking one of the drugs recommended by guidelines for DPN symptom control (32,33) - amitriptyline, duloxetine, gabapentin, pregabalin or capsaicin”
BackgroundThe Epidemiology of Diabetic Neuropathy
Wheeler, S., Singh, N. K., & Boyko, E. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-311-0_2 · Cited by 12
Research works printed but not linked: 1
- Scottish Intercollegiate Guidelines Network, 2010, Management of Diabetes: A National Clinical Guideline
Cited by
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Elafros, M. A., Andersen, H., Bennett, D. L., Savelieff, M. G., Viswanathan, V., Callaghan, B. C., & Feldman, E. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00188-0 · Cited by 387
Diabetic neuropathy: cutting-edge research and future directions
Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02175-1 · Cited by 234
“For example, when using questionnaires like MNSIQ, the prevalence of DN in T1DM patients is estimated at 11 – 13%; 29,30 however, when structured clinical examinations and vibration perception thresholds are used, the prevalence increases to 28%.”
Tobias, D. K., Merino, J., Ahmad, A., Aiken, C., Benham, J. L., Bodhini, D., Clark, A. L., Colclough, K., Corcoy, R., Cromer, S. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02502-5 · Cited by 217
Metadata
- Authors
- Jeyam, A., McGurnaghan, S. J., Blackbourn, L. A. K., McKnight, J. M., Green, F., Collier, A., McKeigue, P. M., & Colhoun, H. M.
- Affiliations
- Institute of Genetics and Cancer (GB)
- NHS Lothian (GB)
- Dumfries and Galloway Royal Infirmary (GB)
- University Hospital Ayr (GB)
- University of Edinburgh (GB)
- National Health Service (GB)
- Corresponding author
- Jeyam, Anita
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-01-23
- Volume
- 43
- Issue
- 4
- Pages
- 734-742
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3002419256
- Semantic Scholar
- 797905057922d7edb07aa82ecfc9c634ef3b3724
- Cited by
- 59
- References
- 38
- Citations by year
- 2026: 5 · 2025: 19 · 2024: 16 · 2023: 6 · 2022: 8 · 2021: 3 · 2020: 2
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (acceptedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Chief Scientist Office (ETM/47)
- Diabetes UK (10/0004010)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Keywords
- diabetic peripheral neuropathy, type 1 diabetes, socioeconomic deprivation, prevalence, risk factors, glycemic control, renal function, smoking, waist-to-hip ratio, lipids, HDL cholesterol, diabetes complications, Michigan Neuropathy Screening Instrument, Scotland
- MeSH terms
- Adolescent, Adult, Cross-Sectional Studies, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Female, Humans, Male, Middle Aged, Risk Factors, Scotland, Socioeconomic Factors, Prevalence, Vulnerable Populations, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.